Topical reproxalap met its primary and secondary endpoints, reducing ocular itch in allergic conjunctivitis patients in a phase 3 trial, Aldeyra Therapeutics announced in a press release.
The double-masked, randomized, vehicle-controlled, multicenter, parallel-group ALLEVIATE trial studied the efficacy of 0.25% and 0.5% concentrations of reproxalap topical ophthalmic solution compared with vehicle.
As assessed by area under the ocular itch score curve, those treated with reproxalap had a statistically significant reduction in ocular itching (P < .0001 for 0.25% and P = .0025 for 0.5%).
Uncategorized